Screener
BioMarin Pharmaceuticals BMRN Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other income, net | 3,279 | 4,833 | 7,240 | 2,879 |
| INCOME BEFORE INCOME TAXES | 61,384 | 297,868 | 202,587 | 535,957 |
| Provision for income taxes | 16,622 | 57,336 | 52,298 | 109,739 |
| NET INCOME | $44,762 | $240,532 | $150,289 | $426,218 |
| EARNINGS PER SHARE, BASIC | $0.23 | $1.25 | $0.78 | $2.23 |
| EARNINGS PER SHARE, DILUTED | $0.23 | $1.23 | $0.77 | $2.19 |
| Weighted average common shares outstanding, basic | 193,423 | 191,907 | 192,959 | 191,440 |
| Weighted average common shares outstanding, diluted | 194,467 | 197,091 | 194,147 | 196,643 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's net income?
- BioMarin Pharmaceuticals (BMRN) reported net income of $44.76M in Q2 2026.
- How has BioMarin Pharmaceuticals's net income changed year-over-year?
- BioMarin Pharmaceuticals's net income decreased by 81.4% year-over-year, from $240.53M to $44.76M.
- What is the long-term trend for BioMarin Pharmaceuticals's net income?
- Over 3 years (2021 to 2024), BioMarin Pharmaceuticals's net income has grown at a 88.2% compound annual growth rate (CAGR), from -$64.08M to $426.86M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about BioMarin Pharmaceuticals's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude